Correlação genótipo-fenótipo em pacientes brasileiras com síndrome de Rett by LIMA, Fernanda T. de et al.
Arq Neuropsiquiatr 2009;67(3-A):577-584
 577
Genotype-phenotype correlation in 
Brazillian rett Syndrome patientS
Fernanda T. de Lima1, Decio Brunoni2, José Salomão Schwartzman3,  
Maria Cristina Pozzi4, Fernando Kok5, Yara Juliano6, Lygia da Veiga Pereira7
abstract – Background: Rett syndrome (RS) is a severe neurodevelopmental X-linked dominant disorder caused 
by mutations in the MECP2 gene.  Purpose: To search for point mutations on the MECP2 gene and to establish 
a correlation between the main point mutations found and the phenotype.  Method: Clinical evaluation of 
105 patients, following a standard protocol. Detection of point mutations on the MECP2 gene was performed 
on peripheral blood DNA by sequencing the coding region of the gene.  Results: Classical RS was seen in 68% 
of the patients. Pathogenic point mutations were found in 64.1% of all patients and in 70.42% of those with 
the classical phenotype. Four new sequence variations were found, and their nature suggests patogenicity. 
Genotype-phenotype correlations were performed.  Conclusion: Detailed clinical descriptions and identification 
of the underlying genetic alterations of this Brazilian RS population add to our knowledge of genotype/
phenotype correlations, guiding the implementation of mutation searching programs.
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correlação genótipo-fenótipo em pacientes brasileiras com síndrome de rett
resumo – Introdução: A síndrome de Rett é uma grave doença do neurodesenvolvimento ligada ao X dominante, 
causada por mutações no gene MECP2.  Objetivos: Identificar mutações de ponto no gene MECP2 e estabelecer 
uma correlação entre as principais mutações encontradas e o fenótipo.  Método: Avaliação clínica de 105 pacientes,  
seguindo um protocolo estabelecido. A identificação de mutações de ponto foi realizada em DNA de sangue pe-
riférico por sequenciamento da região codificante do gene amplificada por PCR.  Resultados: Em 68% dos pacien-
tes observou-se o quadro clássico da síndrome. Mutações de ponto patogênicas foram encontradas em 64,1% dos  
pacientes e em 70,42% das pacientes com o quadro clássico. Quatro novas variações de seqüência foram iden-
tificadas e sua natureza sugere patogenicidade. Correlações genótipo-fenótipo foram estabelecidas.  Conclusão:  
Descrições clínicas detalhadas desta população brasileira de pacientes acrescenta conhecimento às correlações ge-
nótipo-fenótipo nesta grave condição, que podem auxiliar na implantação de programas de triagem de mutações.
PALAVRAS-CHAVE: síndrome de Rett, correlações genótipo-fenótipo.
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Rett syndrome (RS) is an X-linked dominant neurode-
velpmental disorder, with an estimated prevalence of one 
in 15000 girls1. There is a typical evolution of the disease, 
although some of the girls show a variant evolution, and 
are described as the atypical forms of RS1,2.
In 1999, mutations in the MECP2 gene, that encodes 
the methyl-CpG binding protein 2 (MeCP2) were de-
scribed as the cause of RS3. MeCP2 binds to methylated 
CpG dinucleotides, through the methyl binding domain 
(MBD) and is involved in transcriptional silencing of genes 
through the transcriptional repression domain (TRD). The 
nature of the identified mutations indicates that they may 
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cause total or partial loss of protein function4. However, 
results of genotype-phenotype correlations have been in-
consistent across groups5-7.
Since RS is an heterogeneous disorder, the detailed 
study of different patients helps understanding the clinical 
and evolutional variability of the disease. Mutation analy-
sis, on the other hand, allows a better comprehension of 
the mutations’ phenotypic effects, broadening the known 
clinical spectrum. This study was performed to character-
ize MECP2 mutations present in a large cohort of Brazilian 
RS patients, analyzing genotype-phenotype correlations.
method
This study was approved by the Ethics Comittee of Federal 
University of São Paulo – Paulista School of Medicine (UNIFESP-
EPM), protocol number 464/02. It was also approved by the Eth-
ics Comittee of Biomedical Sciences Institute of São Paulo Uni-
versity (USP), protocol number 367. An informed consent was 
requested to the legal responsables of the patients, and only 
those with this document signed were included in the study.
All the 140 patients were examined by neuropediatri-
cians and geneticist, following the same clinical protocol. 
The diagnostic criteria used to classify the patients as classi-
cal RS were those recommended by “The Rett Syndrome Di-
agnostic Criteria Work Group”8. The atypical patients ful-
filled the Hagberg criteria1, excet the minimum age of 10 
years. The majority of the patients were seen at the Brasil-
ian Association of Rett Syndrome in São Paulo, Brazil.
The data collected was used to estimate the clinical severi-
ty and to perform genotype-phenotype correlation. The sever-
ity was estimated using the scale modified by Pineda9.
The molecular investigation was performed at Molecu-
lar Genetics Laboratory of Genetics and Evolutive Biology De-
partment of Bioscience Institute of USP. Genomic DNA was ob-
tained from peripheral lymphocytes10. Point mutations in the 
MEP2 gene were searched by DNA amplification through poli-
merase chain reaction (PCR) and direct sequencing of the prod-
ucts. PCR and sequencing primers were designed to amplify the 
coding region of the gene, in 6 overlapping fragments: 
Exon 2 F-5’-AAAAGGTCGTGCAGCTCAAT-3’; 
R-5’-GATGGCCAAACCAGGACATA-3’; 
Exon 3 F-5’-CTGTTTGGGGGAGGCAGAAG-3’; 
R-5’-CTCCATGAGGGATCCTTGTC-3’; 
Exon 4a F-5’- TGCCCTATCTCTGACATTGC-3’; 
R-5’-CACCACACTCCCCGGCTTTC-3’; 
Exon 4b F-5’-GAAGCGAAAAGCTGAGGCCG-3’; 
R-5’-GGAGCTCTCGGGCTCAGGTG-3’; 
Exon 4e F-5’-CCCCCAAGAAGGAGCACCA-3’; 
R-5’-ACAATGTCTTTGCGCTCTCC-3’; 
Exon 4f F-5’-CCCAAGGAGCCAGCTAAGAC-3’; 
R-5’-CAGAGCCCTACCCATAAGGAG-3’.
Each fragment had specific cycling parameters and all had 
an inicial denaturing of 94oC for 5 minutes and final extension of 
72oC for 10 minutes. Exon 2 and 4a used 30 cycles of 94oC for 45 
seconds, 58oC for 45 seconds and 72 oC for minute. Exon 4b used 
30 cycles of 94oC for 45 seconds, 60 oC for 45 seconds and 72 oC 
for minute. Exons 3, 4e and 4f used 14 cycles of 94oC for 30 sec-
onds, 69 oC for 40 seconds lowering 0.5oC per cycle and 72oC for 
a minute and half, followed by 24 cycles of 94oC for 30 seconds, 
62 oC for 40 seconds and 72 oC for a minute and half. Amplifica-
tion quality was verified in agarosis gel. PCR products were pu-
rified and quantified before been submitted to a sequencing re-
action, on both strands. Reactions were analyzed in automatic 
sequencer ABI Prism model 310, version 3.0, using big dye (Am-
ersham-Pharmacia®), according to the manufacturer’s instruc-
tions. Sequences were compared to normal MECP2 sequence 
(Genbank L37298/AF030876). Thirty-five patients were exclud-
ed because of structural alterations found in the MECP2 gene 
(detected or suspected).
Based on clinical evaluation and point mutations found, a 
genotype-phenotype correlation was performed, with respect 
to presence or absence of mutation, type and location of muta-
tions and between the three most frequent mutations.
Statistical analysis of the results was performed using: (1) 
Chi-square test11, to study associations between groups and stud-
ied variables; (2) Mann-Whitney test11 to confront diferent muta-
tion types and the presence or not of a mutation in relation to 
scores on the Pineda scale9; (3) Kruskal-Wallis variance analysis11 
to study scores on the Pineda scale9 and the location of the mu-
tation and between the three most frequent mutations. The lev-
el of rejection of null hypothesis was fixed in 0.05 or 5%.
reSUltS
Patients
One hundred and forty female patients were evaluat-
ed with clinical hypothesis of RS. Thirty-five patients were 
late excluded because of large structural alterations found 
in the MECP2 gene (detected or suspected). Beetween 
the remaining patients, there were 2 pairs of concordant 
twins. Among the 105 patients, 68% had classical RS and 
27% were atypical. Five patients were not classified due 
to their age, or because they showed an initial very sug-
gestive clinical picture, but the diagnostic criteria were 
impossible to apply; they were categorized as “non-clas-
sified”. The median age of the patients on the first evalu-
ation was 8 years (SD 5.44 years), ranging from 1 year and 
7 months and 27 years and 11 months of age.
Mutations
In total, 84 point variations were found in 74 patients, 
including the 2 pairs of twins, resulting in a frequency of 
detection fo 70% (72/103, considering twins as one) (Fig 1). 
Of them, 68 were considered pathogenic (81% of all vari-
ations), and 4 were not previously described. Twelve were 
silent variations (14.3% of all variations); 1 not previously 
described. Three missense non-pathogenic polymorfisms 
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Fig 1. Mutations and polymorphisms found in the MECP2 gene. Scheme of the MECP2 gene where rectangles represent exons 
2–4, and lines introns. The regions encoding the different functional domains of the MECP2 protein are indicated. Missense mu-
tations and silent polymorphisms are shown above the gene. Polymorphisms found in association with a mutation are placed 
together with the mutation found. Truncating mutations are shown below the gene. Number between parentheses indicate the 
number of patients with that alteration. In bold, mutations in hot spots, and in italic, polymorphisms. MBD: methyl binding do-
main; TRD: transcriptional repression domain; NLS: nuclear location signal. *not previously described mutations.
Fig 2. Distribuition of pathogenic point mutations according to clinical classification of the patients. Scheme of the MECP2 gene 
where rectangles represent exons 2–4, and lines introns. The regions encoding the different functional domains of the MECP2 
protein are indicated. Missense mutations are shown above the gene. Truncating mutations are shown below the gene. The 
first number between parentheses indicate the number of classical patients with that alteration and the second, the number 
of atypical or non-classified patients with that mutation. In bold, mutations in hot spots. MBD: methyl binding domain; TRD: 
transcriptional repression domain; NLS: nuclear location signal. *Not previously described mutations.
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(3.65% of all variations), previously described, and an alter-
ation whose pathogenicity was not been previously deter-
mined were also found (1.1% of all variations). Six patients 
had only non-pathogenic variations (5.8%). C to T transitions 
at CpG islands totalizes 88.1% (74/84). Most of the patho-
genic point mutations were concentrated on the meth-
yl binding domain (MBD) (25/66 – 36%). The frequency of 
pathogenic point mutations was 64.1% (66/103). The distri-
bution of pathogenic point mutations is shown in Figure 2.
Three patients deserve special consideration. Two 
were atypical, one had hyperchromic linear spots and 
normal karyotype and the other had a chromosomal ab-
normality, t(4)(q11);14(q11). None of them had any detect-
ed point mutation. The third patient had a classical phe-
notype but high levels of lactic and pyruvic acids. This pa-
tient had the T158M mutation, previously described. All 
were included because it was considered interesting to 
check if they had MECP2 mutations.
Among the classical patients, the frequency of detec-
tion of pathogenic point mutations was 70.4% (50/71, twins 
considered as 1). Among the atypical patients, the frequen-
cy was 50% (14/28), and among the non-classified patients, 
40% (02/05). The four most frequent mutations amount-
ed to 68% of the pathogenic point mutations detect-
ed in the classical patients and 50% in the atypical ones.
The distribution of pathogenic point mutations de-
tected among the atypical patients was 58.8% (10/17) in 
those with forme fruste; 33.3% (2/6) in those with congen-
ital variation; 66.7% (2/3) in those with late regression and 
none in those with early seizure.
Genotype-phenotype correlation
Presence or absence of a pathogenic mutation – Initially, the 
patients were grouped according to the presence or ab-
sence of a detected pathogenic point mutations (Table 1). 
Patients with pathogenic point mutations are more like-
ly to exhibit the classical form (p=0.056) and breathing ir-
regularities (p=0.006). Patients without detected patho-
genic point mutations presented earlier onset of disease 
(p=0.013).
Type of mutation – The mutations were divided into two 
different groups: (1) missense mutations and (2) truncat-
ing or nonsense mutations (Table 2). Patients with trun-
cating mutations had earlier symptoms, before one year 
of age (p=0.005), as they had higher scores with Pineda 
scale9 (p=0.032) (Table 5).
Location of the mutation – The location of the pathogenic 
point mutations in the MECP2 protein was divided into four 
groups: (1) mutations in the MBD; (2) mutations between 
the MBD and the TRD; (3) mutations in the nuclear loca-
tion signal (NLS) and (4) mutations in the transcriptional 
repression domain (TRD) after the NLS (Table 3). Mutations 
at the terminal carboxi region were not correlated. Patients 
with mutations at NLS had symptoms before one year and 
this almost reached statistical significance (p=0.066). Pa-
tients with mutations in the TRD after NLS were more like-
ly to maintain ability to walk (p=0.010). Patients with muta-
tions in NLS and between domains had higher scores with 
Pineda scale9 in comparison to patients with mutations in 
TRD after NLS, that had lower scores (p=0.027) (Table 5).
Three most frequent mutations – The three most frequent 
pathogenic point mutations, T158M, R306C, R168X, were 
used to perform a more specific genotype-phenotype cor-
relation (Table 4). All of them were more frequent among 
patients with classical form. Patients with the R306C mu-
tation had late symptoms (p=0.007) and were more like-
ly to maintain the ability to walk (p=0.029). They also 
reached lower scores with Pineda scale9 (p=0.021) (Table 5).
Table 1. Rett syndrome patients, with and without detected point mutations, according to studied variables, showing c2 test results.
Variables Patient with detected mutations Patients without detected mutations p value
FormsI
  Classical
  Atypical
50 (78.13%)
14 (50%)
21 (29.58%)
14 (50%) 0.056*
OnsetII
    ≤ 12 months
    > 12 months
32 (48.48%)
34 (51.51%)
26 (74.29%)
09 (25.71%) 0.013**
Positive variables
  Walk
  Loss of hand use
  Word acquisition
  Breathing disorder
  Seizures
  Scoliosis
  Stereotypic hand movements
  Sleep disturbances
36 (72%)
58 (67.44%)
45 (69.23%)
48 (75%)
42 (67.75%)
37 (61.67%)
67 (66.34%)
23 (63.89%)
14 (28%)
28 (32.56%)
20 (30.77%)
16 (25%)
20 (32.25%)
23 (38.33%)
34 (33.67%)
13 (36.11%)
0.139
0.221
0.222
0.006**
0.443
0.443
0.090
0.892
IPair of twins counted as 1, 2 non-classified patients; II2 patients without this information; *significance level almost reached; **statistical significance.
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diScUSSion
Patients
It is known that RS is more frequent and shows a high-
er phenotypic variation than was first realized1. Published 
Brazilian studies grouped few patients12-14 and none per-
formed a molecular caracterization. This is the first study 
in a large group of Brazilian RS patients with molecular 
characterization and genotype-phenotype correlation.
The majority (68%) of the studied patients had the clas-
sical form of the disease. Since the evaluation of a patient 
at an initial stage is more difficult, five of the patients were 
grouped as non-classified. In three of them, there were no 
pathogenic point mutations detected, although they have 
a very suggestive clinical picture. All of these three pa-
tients have less than 2 years, and the clinical follow-up 
will be mandatory for the establishment of a diagnosis.
Mutations
MECP2 mutations have been identified in 70-90% of 
sporadic patients and approximately 50% of familial cas-
es15. In this study, pathogenic mutations were found in 
64.1% of all patients, 70.4% of classical RS patients, 50% 
Table 2. Studied variables in Rett syndrome patients divided according to the type of detected point 
mutation, showing c2 test results.
Variables Missense mutations Truncating mutations p value
FormsI
  Classical
  Atypical
29 (56%)
8 (57.1%)
22 (44%)
6 (42.9%) 0.985
OnsetII
    ≤ 12 months
    > 12 months
12 (32.43%)
25 (67.57%)
19 (67.86%)
9 (32.14%) 0.005**
Positive variables
  Walk
  Loss of hand use
  Word acquisition
  Breathing disorder
  Seizures
  Scoliosis
  Stereotypic hand movements
  Sleep disturbances
22 (61.11%)
33 (57.89%)
28 (63.64%)
24 (51.06%)
24 (57.14%)
23 (63.89%)
38 (57.57%)
12 (54.54%)
14 (38.89%)
24 (42.11%)
16 (36.36%)
23 (48.97%)
18 (42.86%)
13 (36.11%)
28 (42.42%)
10 (45.45%)
0.434
0.642
0.114
0.152
0.927
0.202
0.249
0.802
IPair of twins counted as 1, 2 non-classified patients; II2 patients without this information; **statistical significance.
Table 3. Studied variables in Rett syndrome patients divided according to the location of detected point mutation, showing c2 test 
results.
Variables NLS MBD TRD after NLS Between domains p value
FormsI
  Classical
  Atypical
9 (18%)
2 (14.29%)
20 (40%)
5 (35.71%)
12 (24%)
6 (42.86%)
9 (18%)
1 (7.14%) 0.504
OnsetII
    ≤ 12 months
    > 12 months
7 (63.63%)
4 (36.36%)
9 (37.5%)
15 (62.5)
7 (36.84%)
12 (63.16%)
8 (80%)
2 (20%) 0.066*
Positive variables
  Walk
  Loss of hand use
  Word acquisition
  Breathing disorder
  Seizures
  Scoliosis
  Stereotypic hand movements
  Sleep disturbances
6 (17.14%)
8 (14.29%)
4 (9.30%)
10 (21.74%)
7 (17.07%)
6 (17.14%)
12 (18.46%)
4 (18.18%)
10 (28.57%)
22 (39.29%)
18 (41.86%)
15 (32.61%)
16 (39.02%)
16 (45.72%)
25 (38.46%)
8 (36.36%)
16 (45.71%)
17 (30.35%)
14 (32.56%)
13 (28.26%)
12 (29.27%)
10 (28.57%)
19 (29.23%)
7 (31.81%)
3 (8.57%)
9 (16.07%)
7 (16.28%)
8 (17.40%)
6 (14.63%)
3 (8.57%)
9 (13.85%)
3 (13.63%)
0.010**
0.284
0.087
0.442
0.987
0.336
0.128
0.981
NLS: nuclear location signal (R255X and R270X mutation); MDB: methyl binding domain (R106W, K112X, R133C, R133L, S134P, P152R, D156E, F157L, T58M 
mutations); TRD after NLS: transcriptional repression domain after the NLS (R294X, R306C mutations), between domains (R168X mutation); IPair of 
twins counted as 1, 2 non-classified patients; II2 patients without this information; *significance level almost reached; **statistical significance.
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of atypical patients and 40% of non-classified patients 
(Fig 2). Four pathogenic point mutations were more fre-
quent – T158M, R306C, R168X and R270X, amount to 68% 
of pathogenic point mutations in classical patients and 
50% of atypical patients, indicating that these mutations 
should be initially searched in screening programs with 
Brazilian RS patients.
Four not previously described point mutations were 
found. The first one, K112X, was not described on Rett-
BASE16, a database that collects MECP2 mutations. It was 
found in association with another described alteration, 
S291A, whose pathogenicity was questioned. The amino-
acid K in that position of the MECP2 gene is conserved in 
all species and the mutation leads to an early stop codon, 
and therefore a truncated protein. This suggests that K112X 
is pathogenic and S291A is not.
The other three new mutations were S134P, F157L and 
X487L. At codon 134, there have been 2 different mutations 
described: S134C, pathogenic, and S134F, whose pathoge-
nicity is unknown16. This is a conserved residue in MBD 
in all species, polar, whith a hydrophilic behaviour, and 
it was substitute by a non-polar hydrophobic aminoacid, 
which suggest that S134P should be pathogenic. At codon 
157, there have also been 2 different mutations described: 
F157fs, pathogenic and F157I, whose pathogenicity is un-
known. This is also a conserved aminoacid in all species, 
which suggest pathogenicity. The mutation X487L abolishes 
the final codon, which prevents the stop of the transcrip-
tion, leading to a large protein, suggesting pathogenicity.
The classical patient with higher lactic and pyruvic ac-
ids had the T158M mutation. The elevation of blood levels 
of lactic acid and/or pyruvic acid is found in a substan-
tial proportion of patients with RS and can be associat-
ed with ventilation disturbances17. The identification of a 
pathogenic mutation in this patient reinforces the find-
ings of Huppke et al.18 , who emphasized that the diag-
nosis of RS should not be dismissed because some char-
acteristic features are absent or because uncharacterisic 
symptoms are present. 
In this study, only the coding region of MECP2 has been 
analyzed, and mutations in regulatory elements could ac-
count for those cases in which no mutation has been iden-
tified15. In addition, PCR-based techniques could miss the 
altered gene if there is large rearrangements. Without am-
Table 4. Rett syndrome patients with the three most frequent detected point mutations, according to studied 
variables, showing c2 test results.
Variables R306C T158M R168X p value
FormsI
  Classical
  Atypical
9 (31%)
3 (50%)
11 (37.9%)
2 (33.3%)
9 (31%)
1 (16.7%) 0.653
OnsetII
    ≤ 12 months
    > 12 months
4 (30.77%)
9 (69.23%)
2 (16.67%)
10 (8.33%)
8 (80%)
2 (20%) 0.007**
Positive variables
  Walk
  Loss of hand use
  Word acquisition
  Breathing disorder
  Seizures
  Scoliosis
  Stereotypic hand movements
  Sleep disturbances
11 (52.38%)
11 (35.48%)
10 (40%)
8 (36.36%)
8 (36.36%)
7 (38.89%)
13 (37.14%)
4 (36.36%)
7 (33.33%)
11 (35.48%)
8 (32%)
6 (27.27%)
8 (36.36%)
8 (44.44%)
13 (37.14%)
4 (36.36%)
3 (14.29%)
9 (29.03%)
7 (28%)
8 (36.36%)
6 (27.27%)
3 (16.67%)
9 (25.71%)
3 (27.27%)
0.029**
0.916
0.695
0.256
0.996
0.306
0.263
0.999
IPair of twins counted as 1, 1 non-classified patient; II1 patient without this information; **statistical significance.
Table 5. Pineda score means in Rett syndrome patients, divided 
according the various groups, showing Mann-Whitney and 
Kruskal-Wallis tests results.
Patients divided according to: Mean p value
Presence of point mutationI
  With point mutation detected
  Without point mutation detected
16.969
17.543 0.511
Mutation typeI
  Missense
  Truncating
16.319
18.074 0.032**
Location of mutationII
  NLS
  MBD
  TRD after NLS
  Interdomain
17.909
16.957
15.316
18.909 0.027**
Most frequent mutationsII
  R306C
  T158M
  R168X
15.077
17.091
19.444 0.021**
NLS: nuclear location signal (R255X and R270X mutation); MDB: methyl 
binding domain (R106W, K112X, R133C, R133L, S134P, P152R, D156E, F157L, 
T58M mutations); TRD after NLS: transcriptional repression domain after 
the NLS (R294X, R306C mutations), between domains (R168X mutation); 
IMann-Whitney test; IIKruskal-Wallis test. **statistical significance.
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plification of the mutated allele, only the normal allele is 
amplified, resulting in false-negative results, and account-
ing for detection rates lower than a 100%19.
A recently published recommended screening strat-
egy is to firstly screen exons 3 and 4 for mutations using 
PCR-based techniques20. If no mutation is identified, fur-
ther screening of exons 1 and 2 is reccomended. For in-
dividuals in whom no pathogenic mutations have been 
found, additional screening for large deletions is recom-
mended, which may be achieved by Southern analysis, 
quantitative PCR or multiplex ligation prove amplifica-
tion (MLPA). Patients who are negative for MECP2 muta-
tions and have a strong clinical diagnosis of RS, particular-
ly if there are early onset seizures, should be considered 
for further screening of the CDKL5 gene, recently associ-
ated with this variant20.
Genotype-phenotype correlations
The discovery of a molecular alteration related to RS 
raised questions about a possible genotype-phenotype 
correlation; however various studies in different popula-
tions have yielded inconsistent results6,7,21-24.
There are different genetic factors that are likely to 
influence the phenotype in RS, including patterns of X 
chromosome inactivation and the type and location of 
the mutation. Several studies have demonstrated normal 
X inactivation patterns in the majority of RS cases, so this 
should be an important factor in a minority of patients5,24.
Presence or absence of a pathogenic mutation – Before cor-
relating the different types or locations of the mutations 
and the phenotype, a correlation between the presence 
or absence of a pathogenic mutation and the clinical pic-
ture was done (Table 1). It was observed that most patients 
with an unidentified pathogenic point mutation (74.3%) 
had an earlier onset of symptoms, before one year of age. 
A similar observation was made in 20 Korean RS patients, 
where there was a tendency for patients with no detect-
ed MECP2 mutation (30%) to show more severe symp-
toms and more rapid clinical progression23. We suggest 
that these patients have large structural abnormalities in 
the MECP2 gene, not detectable by our screening strate-
gy, causing total loss of protein function and therefore the 
earlier disease presentation. Additional molecular meth-
odologies are necessary to confirm this hypothesis.
In this study, breathing abnormalities were significant-
ly more frequent in patients with identified point muta-
tions. Breathing abnormalities are a striking feature of RS 
that occurs during wakefulness5, and its association with a 
point mutation reinforces the specificity of the mutations 
in respect of the classical phenotype. Additional associa-
tions observed in patients with detected mutations were 
pointed by Bienvenu et al.25, that showed that patients 
with detected mutation lost more frequently acquired 
purposefull hand skills, had more frequent peripehral va-
somotor disturbances and epilepsy and were more fre-
quently able to walk, although statistically not significant. 
Type of mutation – Several groups tried to determine 
whether different types of mutations in the MECP2 gene 
can account for the variability of clinical features. We di-
vided the mutations found in this study in two different 
groups: missense and truncating mutations (Table 2). In 
agreement with other studies6,24,26,27, we found that pa-
tients with truncating mutations had earlier symptoms 
and higher scores with Pineda scale9 (Table 5), indicating 
that these mutations are more deleterious to the protein. 
Location of the mutation – The mutations were also 
grouped according to their location in the different re-
gions of the MECP2 gene (Table 3), and it is expected that 
mutations in more important functional protein regions 
lead to more severe phenotypes. Indeed, we found that 
mutations in the NLS lead to earlier disease onset and 
higher scores with Pineda scale9. In contrast, patients with 
mutations in the TRD domain after the NLS had lower 
scores, presenting the atypical form of the disease. 
These results are similar to those of Colvin et al.28, and 
they indicate that mutations involving the NLS may re-
sult in failure of the protein to be directed to the nucle-
us, resulting in a more significant reduction of MECP2 pro-
tein function, which in turn would lead to a more severe 
phenotype. Proteins carrying mutations distal to the NLS 
might still be targeted to the nucleus and exert a partial 
effect on transcription repression28.
Three most frequent mutations – Finally, the three most 
common mutations were considered individually (Table 
4), searching to a more precise genotype-phenotype cor-
relation. It might happen that a specific mutation could 
be responsible for a specific symptom or cause a more se-
vere phenotype.
All of the three mutations were more frequent in clas-
sic RS. In accordance with other studies27,29, we observed 
that the R306C mutation was associated with a milder 
form of RS that included later disease onset, lower scores 
with Pineda scale9, and more frequently retention of the 
ability to walk. A functional assay showed that R306C 
mutation retained the ability to repress transcription, ac-
counting for the milder phenotypes30.
We found that presence, type and location of muta-
tions do not influence all features of RS in the same way, 
as observed by other studies5-7,18,20-29. It is necessary more 
studies on protein function and genotype-phenotype cor-
relations with higher number of patients to better inter-
pret these findings.
In conclusion, this is the first study with molecular 
characterization of a large sample of Brazilian RS patients. 
A genotype-phenotype correlation was shown, provid-
ing valuable information necessary for genetic and clin-
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ical counseling. Although still tentative, genotype-phe-
notype correlations helps answering questions raised by 
parents and caretakers about the meaning of a particular 
molecular alteration found. When a negative test result 
is obtained, it should be emphasized that additional mo-
lecular alterations could be present, not detected by the 
methodology used, or different altered genes could be 
involved and, because of that, the clinical interpretation 
of this result should be made with caution. The results 
also show that mutation screening in Brazilian RS patients 
should begin by searching for the four most frequent mu-
tations identified here. It is also suggested that methods 
that detect large deletions should be used, mostly when 
analyzing early onset and atypical patients.
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